Core Insights - The article highlights the significant milestone achieved by the company, Xianweida Biopharmaceutical, with the approval of its innovative product, Enoglutide injection, by the NMPA for the treatment of type 2 diabetes, marking it as the world's first cAMP-biased GLP-1 receptor agonist approved for market [1][3]. Group 1: Product Innovation and Market Position - Enoglutide injection utilizes a unique cAMP-biased mechanism, allowing for targeted activation of the GLP-1 receptor's downstream cAMP signaling pathway, which enhances metabolic benefits while effectively lowering blood sugar levels [3][4]. - The product has received recommendations in the "2024 China Diabetes Prevention and Treatment Guidelines," indicating a shift towards precise signal regulation in diabetes treatment [3][4]. Group 2: Clinical Data and Efficacy - Two pivotal Phase III clinical studies (EECOH-1 and EECOH-2) demonstrated that Enoglutide injection provides significant benefits in blood sugar reduction, weight loss, and improvement in various metabolic indicators, with sustained efficacy for up to 52 weeks [4][6]. - The results of the EECOH-1 study have been published in the prestigious journal "Nature Communications," receiving recognition from leading experts in the diabetes and weight loss fields, underscoring the product's efficacy and safety [4][6]. Group 3: Market Potential and Growth Drivers - The approval of Enoglutide injection positions the company to enter the multi-billion-dollar GLP-1 market, with the global diabetes direct health expenditure surpassing $1 trillion in 2024 and the number of diabetes patients projected to rise to 853 million by 2050 [6][7]. - China, having the highest number of diabetes patients globally, offers a vast market opportunity for the commercialization of Enoglutide injection [6][7]. Group 4: Pipeline and Future Prospects - The company has initiated clinical studies for Enoglutide injection targeting weight loss and non-alcoholic fatty liver disease (NASH), which could enhance its market value and expand its patient coverage [7][9]. - The company is developing a diverse pipeline, including oral formulations and other innovative products, which are expected to address unmet clinical needs and strengthen its competitive position in the weight management sector [9][10]. Group 5: Capital Market and Growth Strategy - The company is in the process of listing on the Hong Kong Stock Exchange, which is anticipated to provide funding for R&D and commercialization efforts, thereby accelerating market penetration of its core products [12]. - The successful commercialization of Enoglutide injection and the advancement of other pipeline products are expected to enhance the company's profitability and growth potential [12].

Core Viewpoint - The A-share market is experiencing a steady upward trend in 2026, shifting from a liquidity-driven market in 2025 to a focus on high-performing companies, with improved corporate earnings expected to be the core support for the market [1] Group 1: Market Trends - The current preference for the AI chip and memory chip sectors, exemplified by the ETF Huatai (588750), is driven by the anticipated improvement in corporate earnings [1] - Historical data suggests that industries with sustained recovery during earnings forecast periods typically yield excess returns, with the current recovery signals concentrated in price increase chains, high-end manufacturing, and AI chains [1] Group 2: Chip Sector Dynamics - The AI wave is creating significant opportunities in the industry chain, leading to a structural reconfiguration in the storage chip market, characterized by a super cycle of price increases driven by AI demand [3] - The storage chip market is expected to remain in a state of supply-demand imbalance, with global storage chip prices projected to rise by 30% to 40% in Q1 2026 [3][5] Group 3: Supply and Demand Forecast - For 2026, the supply growth for DRAM is estimated at 15% to 20%, while demand growth is projected at 20% to 25%. For NAND, supply growth is expected to be 13% to 18%, with demand growth at 18% to 23% [5] - Specific price increase predictions for storage products include over 40% for DDR5 RDIMM memory and 20% to 30% for enterprise-grade SSDs [5] Group 4: AI and Computing Power Demand - The demand for computing power is expected to grow exponentially as AI transitions from training to large-scale inference, leading to a supply shortage in CPU/GPU/DCU chips [6] - Major chip manufacturers are planning to raise prices by 10% to 15% due to the extreme supply-demand imbalance caused by surging AI demand [6] Group 5: Domestic Innovation and Policy Support - The push for domestic innovation and replacement in the chip sector is gaining momentum due to escalating external restrictions and surging internal demand, supported by top-level design and policy funding [7] - The new five-year plan emphasizes the need for self-reliance in technology, with a focus on chip autonomy as a critical infrastructure for AI development [7]

从"缺芯少屏"的窘迫到全球面板产能占比超七成的逆袭，中国显示产业用二十年跑完了上半场的规模追 赶。 而下半场的高端突围战，考验的不仅是技术硬实力，更是供应链自主可控的深层底气。 Omdia数据显示，2025年中国OLED面板出货量占比达48.8%，与韩国几乎持平，但在中大尺寸高端市 场，核心设备与工艺的自主突破仍有提升空间。 如何摆脱对国外技术路线的依赖，走出一条自主可控的高世代线发展路径，是一场关乎未来数十年产业 安全与竞争力的"必修课"。近日，新华社《扬声》节目专题采访维信诺董事长张德强博士，讲述中国显 示产业如何从曾经的技术高度依赖进口的"无人区"，向领跑全球的"无人区"挺进。 高世代线之争，一场绕不开的高端局 高世代线，是OLED技术向电视、笔记本等中大尺寸市场渗透的关键门票。 全球头部玩家早已加速布局：目前，面向高世代线的技术探索主要分为两大路径： 一是基于精细金属掩模版（FMM）的传统蒸镀路线，这也是三星、京东方的选择。 二是旨在彻底摆脱FMM限制的"无FMM"路线。其中，"无FMM"路线又衍生出不同的技术分支，例如维 信诺采用的半导体光刻（ViP）技术，以及TCL押注的印刷OLED技术。不同路线 ...

他表示，从自主设计到核心设备自研，从工业机器人到机床全产业链自主可控，董总（董明珠）带领格 力脚踏实地，不借外援、不抄捷径，一砖一瓦筑牢中国智造根基。这份硬实力，是格力的底气，更是中 国制造的底气！为格力，为中国智造喝彩！ 责任编辑：李思阳 1月29日消息，珠海格力电器股份有限公司市场总监朱磊发微博表示，格力领航级智能工厂登上新闻联 播，这份国家级认可，是格力深耕自主创新的最好答卷。 他表示，从自主设计到核心设备自研，从工业机器人到机床全产业链自主可控，董总（董明珠）带领格 力脚踏实地，不借外援、不抄捷径，一砖一瓦筑牢中国智造根基。这份硬实力，是格力的底气，更是中 国制造的底气！为格力，为中国智造喝彩！ 1月29日消息，珠海格力电器股份有限公司市场总监朱磊发微博表示，格力领航级智能工厂登上新闻联 播，这份国家级认可，是格力深耕自主创新的最好答卷。 责任编辑：李思阳 ...

实现这一突破，吴桂琴团队用了近二十年的时间。 早在读书期间，吴桂琴跟随导师鉴定企业进口种鸡时才得知，我国的蛋鸡种源竟然80%以上要依赖进 口。而国内企业引种时，也总要看国际育种公司的脸色，时间、数量、质量和价格通通没有话语权。加 上进口种鸡有核心技术保护，不能直接用来育种，种源被"卡脖子"，自然也就没法保证鸡蛋的稳定供 应。 本报记者 骆倩雯 "我们可以很自豪地说，中国人每吃2枚鸡蛋，就有1枚来自京系蛋鸡。" 北京市华都峪口禽业有限责任公司副总经理 吴桂琴 中国人每吃2枚鸡蛋，就有1枚来自京系蛋鸡。女博士吴桂琴和她的团队，让中国有了自己的蛋鸡种源， 实现了"吃蛋自由"。 有一个场景至今还深深地刻在吴桂琴的脑海里。读博期间她到美国公派留学，参加了国际蛋鸡育种公司 的全球技术培训班。在参观实验室时，技术人员拿出一个试管，往里面滴了一滴液体后轻轻摇动，当出 现絮状沉淀后他神情骄傲地告诉大家"这就是鸡的基因组DNA"。"当时来自全球各地的客户都露出了惊 异的表情，赞叹不已，而我的内心却五味杂陈，因为这样的操作正是我读研期间熬夜苦干的常规动作， 压根不是什么稀奇的技术。"吴桂琴懂了，商业育种的核心技术并不是高不可攀，况 ...

央企作为科技创新排头兵，应当将优化创新生态作为基础发力点。 1月28日，国新办举行新闻发布会，邀请国务院国资委相关负责人介绍2025年国资央企高质量发展情 况。其中指出，当前央企已经在科技创新、战略性新兴产业和未来产业布局上取得了一系列重大突破， 新质生产力发展正在积厚成势。 在积极推进研发成果高效率转化方面，要充分发挥央企对创新链、产业链、资金链的集成作用，强化产 学研协同，打造要素共投、收益共享、风险共担的联合创新体系。 持续加大研发投入带来的是创新成效不断显现。2025年这一年，央企围绕国家战略和重大需求，牵头或 参与了全部22个国家重大科技专项，攻克领跑技术121项，天问二号、首艘电磁弹射型航母等一批"大国 重器"捷报频传，"天权""钢铁脊梁号"等重大创新成果竞相涌现。 国资委相关负责人表示，今年央企将进一步增强责任感使命感，大力强化自主创新、原始创新，为实现 高水平科技自立自强、建设科技强国提供有力支撑；就"十五五"时期来说，要充分发挥央企科技创新主 体作用，加强自主创新、原始创新和关键核心技术攻关，加上其他措施的协同，更好催生新质生产力。 央企要进一步在发展新质生产力上积厚成势，持续加大研发投入是 ...

此外，中央企业围绕国家战略和重大需求，牵头或参与全部22个国家重大科技专项，攻克领跑技术121 项，天问二号、首艘电磁弹射型航母等一批"大国重器"捷报频传，"天权"、"钢铁脊梁号"等重大创新成 果竞相涌现。 张剑龙表示，今年，国资央企将进一步增强责任感使命感，大力强化自主创新、原始创新，为实现高水 平科技自立自强、建设科技强国提供有力支撑。重点在三个方面发力：着力增加高质量的科技供给。加 强关键核心技术攻关，提高基础研究投入占比，深化原创技术策源地建设，集中力量攻克一批辐射性、 全局性、战略性技术，产出更多原创性、引领性重大科技成果。着力推进高效率的成果转化。发挥中央 企业链长和应用场景双牵引作用，加快布局建设一批中试验证平台，加大首台（套）、首批次、首版次 采购力度，推动更多创新成果转化为现实生产力。着力构建高水平创新生态。充分发挥中央企业对创新 链、产业链、资金链的集成作用，强化产学研协同，打造要素共投、收益共享、风险共担的联合创新体 系，助力增强国家创新体系优势。 （文章来源：新华财经） 新华财经北京1月28日电（记者沈寅飞）在国新办28日举行的新闻发布会上，国务院国资委科技创新局 局长张剑龙介绍，中央 ...

（来源：经济参考报） 工业强、江西强。"十四五"以来，江西紧扣实现新型工业化关键任务，深入实施"1269"行动计划，全部 工业增加值保持在万亿元以上，工业营业收入保持在4万亿元以上，高质量发展成色更足。 其背后，材料科学的创新支撑作用日益凸显。"1269"行动计划重点培育的12条制造业重点产业链和6个 先进制造业集群中，材料创新正是贯穿多领域、赋能产业升级的核心元素之一。 产业所需，正是科研所向。作为江西省唯一的国家"双一流"建设学科，南昌大学材料科学与工程学科 （以下简称"南昌大学材料学科"）坚持从产业发展痛点出发，以材料创新夯实工业根基，推动人才链、 创新链与产业链深度融合，已成为服务国家战略和区域高质量发展的重要"智力引擎"。 不是"能做什么" "传统无氧铜材沟槽管在持续高温下易软化变形，难以满足大功率器件长时间散热需要。"耐乐铜业总工 程师马力表示，无氧铜材沟槽管的散热"短板"，曾一度制约了国产高端散热模组向更高性能迈进。 2021年，南昌大学卓海鸥团队深入耐乐铜业生产一线，将实验室的前沿理念与产业端的实际痛点对接， 通过在无氧铜中添加微量稀土元素，使新型铜材的强度和高温性能显著提升。2024年，仅这 ...

李坤元强调，真正引领市场的主线需政策规划与产业趋势共振。她重点关注多个产业方向，重点聚 焦"新质生产力"，掘金优质公司。此外，她认为2026年可能会有多重利好出现，例如：PPI触底带来部 分顺周期行业的基本面改善、AI和自主创新带来科技产业进入新的发展阶段、居民资产配置有望向权 益迁移、以及中国影响力提升等。在上述多种积极因素共振下，A股有望迎来新一轮上涨行情。 针对年初市场，李坤元指出，短期"开门红"行情可能受到增量资金流入与风险偏好提升等多重因素驱 动，但中长期市场是对各行业未来基本面变化的反应。她认为，结构性行情演绎至历史高估值区域后， 市场大概率进入震荡调整阶段，需等待产业催化和业绩验证。 中证报中证网讯（郝健）宏利基金权益部执行总经理、基金经理李坤元1月27日晚间在"中证点金汇"直 播间表示，当前财政与货币政策的协同发力，不仅为市场提供了流动性支持、稳定了宏观预期，也为宏 观政策聚焦的"新质生产力"与"科技自立自强"等长期产业升级创造了平稳环境。 ...

Core Viewpoint - The A-share market is experiencing fluctuations, but the sci-tech chip sector is showing resilience and strength, with significant capital inflow driven by "AI catalysis and independent innovation" [1][6]. Group 1: Market Performance - As of 11:01 on January 27, the sci-tech chip ETF Huatai (588750) rose by 2%, with over 220 million yuan net inflow for three consecutive days [1]. - Major component stocks of the sci-tech chip ETF saw significant gains, with Dongxin Co. hitting the daily limit, and other stocks like Chip Source Micro and Yuanjie Technology rising over 14% and 11% respectively [3][4]. Group 2: Industry Trends - The chip sector is receiving strong financial support, with the Shanghai three major leading industries mother fund announcing the selection of 17 sub-funds, including 4 for integrated circuits, totaling 22.89 billion yuan [6]. - The demand for storage chips is driven by AI, with a structural reconfiguration leading to price increases in high-end storage products like HBM and DDR5, expected to continue through 2026 [7]. - The demand for computing chips is surging as AI transitions from training to large-scale inference, resulting in a supply-demand imbalance across all categories of computing chips [8]. Group 3: Domestic Innovation and Market Opportunities - Domestic innovation and localization are accelerating in the chip industry, supported by top-level design and policy funding, creating a rapid growth window for domestic computing leaders [10]. - The domestic equipment procurement rate is projected to rise from approximately 18% in 2022 to around 30% by 2025, with potential growth to 60%-70% in the future [11]. - The sci-tech chip sector is positioned to benefit from both AI demand and domestic substitution, with the Huatai ETF focusing on core segments of the chip industry, showcasing higher growth potential and elasticity [12][14]. Group 4: Investment Insights - The Huatai sci-tech chip ETF is expected to show a net profit growth rate of 94% in the first three quarters of 2025, significantly outperforming peers [14]. - The ETF has demonstrated a maximum increase of 173% since September, indicating strong upward elasticity compared to other industry indices [15].